NVNONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
enVVeno Medical Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$7.69+0.22 (+2.95%)
Close on Oct 19, 2026
- Market cap
- $5.16M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
13.0%
0M of 1M shares
Institutional holders
17
3 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 4 sales
Net sold $4.94K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kingdon Capital Management, L.L.C. | 36,166 | 5.50% | 13G (passive) amendment | Mar 31, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. | 2,048,515 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Thomas A. Satterfield, Jr. | 1,822,500 | 9.00% | 13G (passive) | Nov 14, 2025 |
| Mark Kingdon | 1,359,261 | 7.10% | 13G (passive) | Sep 2, 2025 |
| Wilmot B. Harkey | 1,285,857 | 7.06% | 13G (passive) amendment | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NVNO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Kingdon Capital Management, L.L.C. | 36,166 | 5.30% | $387.34K | – | 0.04% |
| CM Management, LLC | 35,714 | 5.23% | $382.50K | – | 0.25% |
| Vanguard Capital Management LLC | 6,287 | 0.92% | $67.40K | – | 0.00% |
| JPMorgan Chase & Co | 5,208 | 0.76% | $59.11K | −1 | 0.00% |
| Vanguard Fiduciary Trust Co | 2,184 | 0.32% | $23.41K | – | 0.00% |
| Westside Investment Management, Inc. | 1,525 | 0.22% | $16.33K | −64 | 0.00% |
| Mirae Asset Global Investments Co., Ltd. | 539 | 0.08% | $5.77K | New | 0.00% |
| BlackRock, Inc. | 414 | 0.06% | $4.43K | −1,426 | 0.00% |
| Tower Research Capital LLC (TRC) | 331 | 0.05% | $3.55K | −211 | 0.00% |
| Wells Fargo & Company/Mn | 114 | 0.02% | $1.22K | – | 0.00% |
| Allied Private Wealth LLC | 88 | 0.01% | $978 | New | 0.00% |
| Vanguard Global Advisers, LLC | 77 | 0.01% | $825 | – | 0.00% |
| Morgan Stanley | 59 | 0.01% | $632 | −17 | 0.00% |
| Osaic Holdings, Inc. | 7 | 0.00% | $74 | – | 0.00% |
| Group One Trading, L.P. | 2 | 0.00% | $21 | – | 0.00% |
| Barclays PLC | 2 | 0.00% | $21 | New | 0.00% |
| UBS Group AG | 1 | 0.00% | $11 | −242 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 17 | 0M | 13.0% | 3 / 0 | 6 / 3 | 0M | 0M |
| Q1 2026 | 17 | 0M | 14.7% | 17 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NVNO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 6,287 | 0.92% | $67.40K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 5,995 | 0.88% | $67.92K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 841 | 0.12% | $9.53K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 805 | 0.12% | $9.12K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 585 | 0.09% | $6.63K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert Andrew Berman | Chief Executive Officer, Director | 22,236 | 3.26% | Dec 18, 2025 |
| Hamed Alavi | Chief Technology Officer | 8,334 | 1.22% | Dec 18, 2025 |
| Marc H. Glickman | SVP & Chief Medical Officer | 1,600 | 0.23% | Dec 18, 2025 |
| Jennifer Bright | Chief Financial Officer | – | – | May 20, 2025 |
| Francis Duhay | Director | 2,351 | 0.34% | Sep 14, 2026 |
| Matthew Jenusaitis | Director | 16,545 | 2.42% | Dec 15, 2025 |
| Robert Gray | Director | 11,155 | 1.63% | Dec 15, 2025 |
| Sanjay Shrivastava | Director | 9,288 | 1.36% | Dec 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Francis Duhay Director | Sep 11, 2026 | Sale(10b5-1 plan) | −11 | $11.21 | $123 | 2,351 |
| Francis Duhay Director | Jun 11, 2026 | Sale(10b5-1 plan) | −140 | $10.31 | $1.44K | 2,362 |
| Francis Duhay Director | Mar 12, 2026 | Sale(10b5-1 plan) | −140 | $11.52 | $1.61K | 2,502 |
| Francis Duhay Director | Dec 11, 2025 | Sale(10b5-1 plan) | −4,900 | $0.36 | $1.76K | 92,544 |
| Francis Duhay Director | Sep 15, 2025 | Sale(10b5-1 plan) | −4,900 | $0.83 | $4.07K | 97,444 |
| Francis Duhay Director | Dec 31, 2024 | Buy | +81,433 | $3.07 | $250.00K | 102,344 |
| Robert Gray Director | Dec 31, 2024 | Buy | +3,500 | $2.94 | $10.29K | 11,155 |
| Sanjay Shrivastava Director | Dec 24, 2024 | Buy | +5,400 | $2.90 | $15.66K | 9,288 |
| Matthew Jenusaitis Director | Dec 19, 2024 | Buy | +9,620 | $2.53 | $24.34K | 16,545 |
| Robert Andrew Berman Chief Executive Officer, Director | Dec 19, 2024 | Buy | +12,000 | $2.55 | $30.60K | 222,236 |
| Hamed Alavi Chief Technology Officer | Mar 13, 2024 | Option exercise | +8,334 | $3.59 | $29.92K | 8,334 |
| Hamed Alavi Chief Technology Officer | Mar 13, 2024 | Sale | −8,334 | $6.22 | $51.84K | 0 |
| Robert Gray Director | Sep 13, 2022 | Option exercise | +1,041 | – | – | 7,655 |
| Matthew Jenusaitis Director | Sep 13, 2022 | Option exercise | +1,041 | – | – | 6,925 |
| Francis Duhay Director | Aug 16, 2022 | Buy | +7,751 | $6.14 | $47.59K | 20,911 |
| Sanjay Shrivastava Director | Jun 30, 2022 | Buy | +1,000 | $3.85 | $3.85K | 3,888 |
| Robert Andrew Berman Chief Executive Officer, Director | Jun 27, 2022 | Buy | +2,500 | $3.80 | $9.50K | 210,236 |
| Robert Andrew Berman Chief Executive Officer, Director | Nov 30, 2021 | Award | +200,000 | – | – | 207,736 |
| Craig Glynn Chief Financial Officer | Nov 30, 2021 | Award | +50,000 | – | – | 50,000 |
| Marc H. Glickman SVP & Chief Medical Officer | Nov 30, 2021 | Award | +100,000 | – | – | 101,600 |
| Robert Andrew Berman CEO, Director | Nov 19, 2021 | Buy | +2,000 | $7.43 | $14.86K | 7,736 |
| Robert Andrew Berman CEO | Nov 16, 2021 | Buy | +2,000 | $7.87 | $15.74K | 5,736 |
| Sanjay Shrivastava Director | Nov 16, 2021 | Option exercise | +388 | – | – | 2,888 |
| Robert Gray Director | Sep 13, 2021 | Option exercise | +1,042 | – | – | 6,614 |
| Matthew Jenusaitis Director | Sep 13, 2021 | Option exercise | +1,042 | – | – | 5,884 |
| Matthew Jenusaitis Director | Aug 25, 2021 | Buy | +1,300 | $7.70 | $10.01K | 4,842 |
| Robert Gray Director | Jun 16, 2021 | Buy | +2,000 | $6.25 | $12.50K | 5,572 |
| Marc H. Glickman SVP & Chief Medical Officer | May 21, 2021 | Buy | +1,600 | $5.90 | $9.44K | 1,600 |
| Robert Andrew Berman Chief Executive Officer, Director | May 18, 2021 | Buy | +3,000 | $5.47 | $16.41K | 3,736 |
| Francis Duhay Director | May 17, 2021 | Buy | +9,492 | $5.33 | $50.59K | 13,160 |
| Biodyne Holding, S.A. – | Aug 21, 2020 | Sale | −75,000 | $0.38 | $28.50K | 1,405,433 |
| Biodyne Holding, S.A. – | Aug 20, 2020 | Sale | −75,000 | $0.27 | $20.25K | 1,480,433 |
| Biodyne Holding, S.A. – | Aug 19, 2020 | Sale | −50,000 | $0.30 | $15.00K | 1,555,433 |
| Biodyne Holding, S.A. – | Aug 18, 2020 | Sale | −50,000 | $0.34 | $17.00K | 1,605,433 |
| Biodyne Holding, S.A. – | Aug 14, 2020 | Sale | −50,000 | $0.31 | $15.50K | 1,655,433 |
| Biodyne Holding, S.A. – | Aug 3, 2020 | Sale | −70,000 | $0.32 | $22.40K | 1,705,433 |
| Biodyne Holding, S.A. – | Jul 31, 2020 | Sale | −5,000 | $0.34 | $1.70K | 1,775,433 |
| Biodyne Holding, S.A. – | Jul 30, 2020 | Sale | −25,000 | $0.32 | $8.00K | 1,780,433 |
| Biodyne Holding, S.A. – | Jul 21, 2020 | Sale | −50,000 | $0.45 | $22.50K | 1,805,433 |
| Biodyne Holding, S.A. – | Jul 20, 2020 | Sale | −150,000 | $0.43 | $64.50K | 1,855,433 |
| Matthew Jenusaitis Director | Jul 18, 2020 | Award | +62,500 | – | – | 62,500 |
| Robert Gray Director | Jul 18, 2020 | Award | +62,500 | – | – | 78,250 |
| Sanjay Shrivastava Director | Jul 18, 2020 | Award | +62,500 | – | – | 97,500 |
| Francis Duhay Director | Jul 18, 2020 | Award | +62,500 | – | – | 107,228 |
| Biodyne Holding, S.A. – | Jul 17, 2020 | Sale | −50,000 | $0.38 | $19.00K | 2,005,433 |
| Biodyne Holding, S.A. – | Jul 16, 2020 | Sale | −50,000 | $0.38 | $19.00K | 2,055,433 |
| Biodyne Holding, S.A. – | Jul 6, 2020 | Sale | −6,450 | $0.39 | $2.52K | 2,105,433 |
| Biodyne Holding, S.A. – | Jul 2, 2020 | Sale | −57,000 | $0.40 | $22.80K | 2,111,883 |
| Biodyne Holding, S.A. – | Jul 1, 2020 | Sale | −45,000 | $0.38 | $17.10K | 2,168,883 |
| Biodyne Holding, S.A. – | Jun 29, 2020 | Sale | −68,094 | $0.39 | $26.56K | 2,213,883 |
| Biodyne Holding, S.A. – | Jun 26, 2020 | Sale | −80,000 | $0.38 | $30.40K | 2,281,977 |
| Biodyne Holding, S.A. – | Jun 25, 2020 | Sale | −100,000 | $0.40 | $40.00K | 2,361,977 |
| Biodyne Holding, S.A. – | Jun 24, 2020 | Sale | −55,530 | $0.42 | $23.32K | 2,461,977 |
| Biodyne Holding, S.A. – | Jun 23, 2020 | Sale | −80,000 | $0.43 | $34.40K | 2,517,507 |
| Biodyne Holding, S.A. – | Jun 22, 2020 | Sale | −63,186 | $0.46 | $29.07K | 2,597,507 |
| Biodyne Holding, S.A. – | Jun 19, 2020 | Sale | −80,000 | $0.46 | $36.80K | 2,660,693 |
| Biodyne Holding, S.A. – | Jun 18, 2020 | Sale | −61,640 | $0.45 | $27.74K | 2,740,693 |
| Biodyne Holding, S.A. – | Jun 17, 2020 | Sale | −203,100 | $0.48 | $97.49K | 2,802,333 |
| Biodyne Holding, S.A. – | Jun 16, 2020 | Sale | −150,000 | $0.43 | $64.50K | 3,005,433 |
| Biodyne Holding, S.A. – | Jun 15, 2020 | Sale | −100,000 | $0.42 | $42.00K | 3,155,433 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Francis Duhay Director | Sep 11, 2026 | 11 | $123 | Sep 11, 2026 | OPEN MARKET PURCHASE |
| Francis Duhay Director | Jun 11, 2026 | 140 | $1.44K | Jun 11, 2026 | OPEN MARKET PURCHASE |
| Francis Duhay Director | Mar 12, 2026 | 140 | $1.61K | Mar 12, 2026 | OPEN MARKET PURCHASE |
| Francis Duhay Director | Sep 15, 2025 | 9,800 | $8.14K | Sep 15, 2025 | OPEN MARKET PURCHASE |